Figure 1 | Scientific Reports

Figure 1

From: Both anti-inflammatory and antiviral properties of novel drug candidate ABX464 are mediated by modulation of RNA splicing

Figure 1

Analysis of HIV splicing following ABX464 treatment. (A) Organization of the HIV-1 genome and different mRNA splicing products. The 5′ ss (D1–D4) and 3′ ss (A1–A7) are indicated. ORFs of the coding exons of each mRNA product are indicated with a different color code indicating the corresponding encoded proteins of the HIV genome. The non-coding exons are boxed in gray. (B) Inhibition of HIV-1 replication measured by p24 production in PBMCs from six donors. (C) Quantification of HIV splicing events using RNA CaptureSeq in PBMCs from six different donors that were infected and untreated (DMSO) or treated with ABX464 for 6 days (464). Counts of spliced and unspliced contigs are shown. The different splicing products are colored as in A. (D) Sequence of the new viral RNA generated by splicing.

Back to article page